title: Successful Re-treatment of Hepatitis C Virus in Patients Coinfected With HIV Who Relapsed After 12 Weeks of Ledipasvir/Sofosbuvir.
abstract: We assessed the efficacy and safety of ledipasvir/sofosbuvir plus ribavirin for 24 weeks in 9 human immunodeficiency virus/hepatitis C virus-coinfected patients who relapsed after receiving 12 weeks of treatment with ledipasvir/sofosbuvir. Eight of 9 (89%) achieved sustained virologic response 12 weeks after the end of treatment. One patient relapsed at posttreatment week 4. These results suggest an effective salvage therapy for patients for whom direct-acting antiviral treatment has failed.
  
  
  
  NCT02073656.
authors.affiliation: University of Ottawa, Ontario, Canada.
authors.forename: Curtis
authors.initials: C
authors.lastname: Cooper
authors.affiliation: Duke Clinical Research Institute and Duke University School of Medicine, Durham, North Carolina.
authors.forename: Susanna
authors.initials: S
authors.lastname: Naggie
authors.affiliation: University of Alabama at Birmingham.
authors.forename: Michael
authors.initials: M
authors.lastname: Saag
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: Jenny C
authors.initials: JC
authors.lastname: Yang
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: Luisa M
authors.initials: LM
authors.lastname: Stamm
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: Hadas
authors.initials: H
authors.lastname: Dvory-Sobol
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: LingLing
authors.initials: L
authors.lastname: Han
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: Phillip S
authors.initials: PS
authors.lastname: Pang
authors.affiliation: Gilead Sciences, Foster City, California.
authors.forename: John G
authors.initials: JG
authors.lastname: McHutchison
authors.affiliation: Mount Sinai Medical Center, New York, New York.
authors.forename: Douglas
authors.initials: D
authors.lastname: Dieterich
authors.affiliation: Johns Hopkins Hospital, Baltimore, Maryland.
authors.forename: Mark
authors.initials: M
authors.lastname: Sulkowski
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000627:therapeutic use*; D001562:Benzimidazoles / Q000627:therapeutic use; D060085:Coinfection; D004359:Drug Therapy, Combination; D005449:Fluorenes / Q000627:therapeutic use; D006678:HIV / Q000187:drug effects; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D016174:Hepacivirus / Q000187:drug effects; D019698:Hepatitis C, Chronic / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008875:Middle Aged; D012008:Recurrence; D012254:Ribavirin / Q000627:therapeutic use*; D016879:Salvage Therapy; D000069474:Sofosbuvir / Q000627:therapeutic use; D017211:Treatment Failure
chemical_list: D000998:Antiviral Agents; D001562:Benzimidazoles; D005449:Fluorenes; C586541:ledipasvir; D012254:Ribavirin; D000069474:Sofosbuvir
keywords: HCV NS5B polymerase inhibitor; HCV/HIV coinfection; NS5A resistance; direct-acting antiviral agents; re-treatment